Navigation Links
Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
Date:3/5/2009

66% of evaluable heavily-pretreated patients in the high dose groups achieved disease stabilization. ProLindac was well tolerated overall.

DALLAS, March 5 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced today positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this monotherapy study 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The maximum tolerated dose of ProLindac was established as well as the recommended dose levels for future combination studies.

"We are very pleased with these results. ProLindac was well tolerated in an absolute sense and relative to commercially-available platinum therapies. We saw significant DACH platinum activity and efficacy in patients at the highest dose levels which is very encouraging given that this study involved monotherapy in a heavily pretreated patient population that typically only respond to an aggressive drug combination," commented Dr. David Nowotnik, Access' Senior Vice President R&D. "The DACH platinum activity level seen benchmarked favorably with published studies of monotherapy oxaliplatin in similar but less heavily pre-treated patient populations. Having achieved the recommended dose for future combination studies, we look forward to moving ahead in the clinic ourselves and with our regional partners."

This 26 patient Phase 2 study explored 3 different dose levels and 2 dosing regimens of ProLindac as a monotherapy treatment for advanced ovarian cancer, to provide data on the monotherapy anticanceractivity and safety of ProLindac. Of pati
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
2. First U.S. Patients Enrolled in the REALISM Continued Access Study
3. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
4. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
5. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
6. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
7. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
8. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
9. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
10. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- UBM Medica US announces that  OncoTherapy ... oncologists and other clinicians gain a better understanding of ... therapies and immunotherapies, discusses some of the latest news ... Every September, Blood Cancer Awareness Month is ... cancers—helping to increase survival rates and improve the quality ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. Merlo ... CVS ), will speak before the National Press Club in ... the company,s recent move to stop selling tobacco products and ... future of health. "Dramatic changes in our health ... providers and government," Merlo has said. "CVS Health has a ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement ... well as US territories and military bases for Femasys, ... to evaluate a woman,s fallopian tubes with standard ultrasound, ... medical device developer of women,s healthcare solutions. Norgenix Pharmaceuticals, ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or ... the largest network of radiotherapy and diagnostic imaging centers in ... ADS for its unaudited consolidated financial results for the second ... ended June 30, 2010. Second ...
Cached Medicine Technology:Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis 2Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 2Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 3Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 4Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 5Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 6Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 7Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 8Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 9Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 10Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 11Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 12
(Date:9/21/2014)... York, New York (PRWEB) September 21, 2014 ... ) continue to move forward in Pennsylvania’s Philadelphia ... According to court documents, the proceeding’s next monthly ... (Risperdal Litigation, case number 100300296) , “Our Firm ... filed Risperdal lawsuits in this litigation. We are ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the ... and GreenGeeks are the best Reseller hosting suppliers in ... hosting supplier. Actually, these companies have outperformed their competitors ... People can get the best web hosting at affordable ... to the manager, reseller hosting is a very popular ...
(Date:9/21/2014)... TX (PRWEB) September 21, 2014 ... Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is ... Global and Chinese Fenofibrate (CAS 49562-28-9) industry. ... of Fenofibrate (CAS 49562-28-9) including its classification, ... global and China’s top manufacturers of Fenofibrate ...
(Date:9/21/2014)... September 21, 2014 More than ... been added over the past month to a ... serious cardiovascular injuries caused by the dialysis concentrate, ... updated on September 15th shows 2,089 cases filed ... District Court, District of Massachusetts. These claims were ...
(Date:9/21/2014)... BambooIndustry.com, an experienced producer of natural bamboo items, has ... http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels are very popular ... discounted prices now, from 10 to 30 percent off. ... are available in many specifications; they are promised to ... finely manufactured by qualified workers. They are specially offered ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... Inc.,(NYSE: ZMH ; SWX: ZMH), a leader in the ... upcoming investor,conferences: -- November 27, 2007 -- 19th Annual ... York, New York, 9:00 a.m. Eastern Time -- December ... York, New York, 9:30 a.m. Eastern ...
... -- China Medical,Technologies Inc. (the "Company") (Nasdaq: ... company that develops, manufactures and markets advanced ... focused ultrasound tumor,therapy systems, today announces the ... and Dr. Yuedong Li as member for ...
... SALEM, Mass., Nov. 19 LaVoie Group, a ... today announced,that it has been selected as agency ... The GI Company, of Framingham, MA. Donna ... engaged in,providing strategic communications counsel and tactical execution ...
... Support for True Wealth Measures: Three-Quarters Say Governments, ... Environmental Progress, BRUSSELS, Belgium, Nov. 19 ... should look beyond,economics, and include health, social and ... believe that economic growth,alone is the most important ...
... November 19 ThalesNano Inc.,and the Christian ... Karl-Franzens-University in Graz today announced a scientific,collaboration ... focus,on the application of flow reactors for ... utilizing ThalesNano,s background in,continuous processing. ThalesNano and ...
... a dollar value has been attached to the high cost ... that reveals a massive annual cost of $34.3 billion -- ... grappling with pain. The price tag of pain includes ... MBF Foundation study The High Price of Pain: The Economic ...
Cached Medicine News:Health News:China Medical Technologies Announces Changes in Board of Directors and Appointment of Chief Technology Officer 2Health News:China Medical Technologies Announces Changes in Board of Directors and Appointment of Chief Technology Officer 3Health News:LaVoie Group Adds Two New Companies to Its Life Science Client Roster 2Health News:GLOBESCAN Survey for the BEYOND GDP Conference, European Parliament, Nov. 19th and 20th 2Health News:GLOBESCAN Survey for the BEYOND GDP Conference, European Parliament, Nov. 19th and 20th 3Health News:ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies 2Health News:ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies 3Health News:First study of Australia's high cost of pain reveals $34 billion price tag 2
... & Transfer System is a patent-pending disposable, ... procedures simpler for the physician and their ... an office-based technique. LipiVage™ improves upon traditional ... a need to centrifuge, decant or expose ...
... Type B) Injectable Solution, the only Botulinum ... demonstrated in numerous published studies to be ... Delivered as a purified, ready-to-use solution, ... a simpler way to significantly reduce abnormal ...
... is a simple, nonsurgical, physician-administered treatment that ... lines between the brows in people from ... is the only treatment of its type ... (FDA). BOTOX® Cosmetic is a purified ...
Inquire...
Medicine Products: